Search hospitals > Virginia > Charlottesville
University of Virginia Cancer Center
Claim this profileCharlottesville, Virginia 22903
Global Leader in Cancer
Global Leader in Ovarian Cancer
Conducts research for Lung Cancer
Conducts research for Recurrence
Conducts research for Leukemia
483 reported clinical trials
31 medical researchers
Summary
University of Virginia Cancer Center is a medical facility located in Charlottesville, Virginia. This center is recognized for care of Cancer, Ovarian Cancer, Lung Cancer, Recurrence, Leukemia and other specialties. University of Virginia Cancer Center is involved with conducting 483 clinical trials across 515 conditions. There are 31 research doctors associated with this hospital, such as William C. Petersen, Linda Duska, MD, Richard D. Hall, and Marilyn Huang.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Ovarian Cancer
Global LeaderStage IV
BRCA1 positive
Stage III
Top PIs
William C. PetersenUniversity of Virginia Cancer Center4 years of reported clinical research
Studies Tumors
Studies Leukemia
30 reported clinical trials
70 drugs studied
Linda Duska, MDUniversity of Virginia Cancer Center4 years of reported clinical research
Expert in Ovarian Cancer
Expert in Cancer
24 reported clinical trials
37 drugs studied
Richard D. HallUniversity of Virginia Cancer Center1 year of reported clinical research
Expert in Non-Small Cell Lung Cancer
Expert in Lung Cancer
17 reported clinical trials
26 drugs studied
Marilyn HuangUniversity of Miami3 years of reported clinical research
Studies Ovarian Cancer
Studies Ovarian Tumors
13 reported clinical trials
39 drugs studied
Clinical Trials running at University of Virginia Cancer Center
Non-Small Cell Lung Cancer
Cancer
Lung Cancer
Ovarian Cancer
Diffuse Large B-Cell Lymphoma
Acute Myeloid Leukemia
Lymphoma
Prostate Cancer
Squamous Cell Carcinoma
Ovarian Carcinoma
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Chemotherapy + Immunotherapy vs. Immunotherapy
for Advanced Lung Cancer
This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab and chemotherapy may help stabilize lung cancer.
Recruiting2 awards Phase 3
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at University of Virginia Cancer Center?
University of Virginia Cancer Center is a medical facility located in Charlottesville, Virginia. This center is recognized for care of Cancer, Ovarian Cancer, Lung Cancer, Recurrence, Leukemia and other specialties. University of Virginia Cancer Center is involved with conducting 483 clinical trials across 515 conditions. There are 31 research doctors associated with this hospital, such as William C. Petersen, Linda Duska, MD, Richard D. Hall, and Marilyn Huang.
Where is University of Virginia Cancer Center located?
To visit the Emily Couric Clinical Cancer Center, located at 1240 Lee St, Charlottesville, VA 22903, you can take U.S. 29 or I-64. Parking is available at the Lee Street Parking Garage, where you can validate your ticket for free parking.
Who should I call to ask about financial aid or insurance network?
**University of Virginia Cancer Center Financial Assistance and Insurance Support**
- **Financial Assistance:** Patients in need can contact UVA Financial Aid at 434.924.8718 or 866.320.9659 (toll-free), or email financialassistance@virginia.edu. Eligibility for financial aid is determined using a sliding scale based on assets, income, and household size. A financial aid calculator is available to estimate eligibility.
- **Insurance Support:** For insurance inquiries, contact UVA Finance at askfinance@virginia.edu. Coverage includes aircraft, professional liability, restitution and recovery for departmental damage, and automobile physical damage insurance.
- **Eligibility for Financial Assistance Program:** Offers a 100 percent discount or free care for medically necessary services to eligible patients. Criteria include being uninsured or underinsured, unable to access other coverage programs, having an annual family income within 300 percent of the Federal Poverty Guidelines, not possessing substantial cash assets, and residing within a 25-mile radius of the service facility.
What insurance does University of Virginia Cancer Center accept?
The University of Virginia Cancer Center accepts a wide range of insurance plans, including government programs (Medicaid, Medicare), Medicaid HMOs (Aetna Better Health, Anthem Healthkeepers Plus, Molina Healthcare, Sentara Community Plan, United Healthcare Community Plan, Virginia Premier), and commercial health plans (Aetna, Anthem, CIGNA, MedCost/Virginia Health Network, Multiplan/PHCS, Sentara Health Plan, Oscar Exchange, Piedmont Community Health Plan, United Healthcare). They also participate in Medicare Advantage Plans (Part C) such as Aetna, Anthem, Cigna Medicare, Clear Spring Health, Humana, Molina Healthcare, Sentara Health Plan, United, and Virginia Premier. Please verify participation, coverage levels, and benefit criteria with your health plan authorized representative prior to receiving services.
What awards or recognition has University of Virginia Cancer Center received?
The University of Virginia Cancer Center, located in Charlottesville, Virginia, is a National Cancer Institute-designated Comprehensive Cancer Center, recognized for its exceptional cancer program. It has been named a "high performing" cancer service by U.S. News & World Report, excelling in lung, colon, and ovarian cancer surgery. Annually, the center secures over $55 million in funded research, significantly advancing cancer treatment through research and clinical trials.